FORM 4
[ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

SALANS LESTER B 		2. Issuer Name and Ticker or Trading Symbol

Forest Laboratories, LLC [ FRX ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE 		3. Date of Earliest Transaction (MM/DD/YYYY)

7/1/2014
(Street)

NEW YORK, NY 10022
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   7/1/2014     D    22478   D   (1) 0   D    
Restricted Stock   7/1/2014     D    2967   D   (2) 0   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)   $45.32   7/1/2014     D         4000      (3) 8/11/2014   Common Stock   4000     (4) 0   D    
Stock Option (Right to Buy)   $40.32   7/1/2014     D         4000      (5) 8/8/2015   Common Stock   4000     (4) 0   D    
Stock Option (Right to Buy)   $46.11   7/1/2014     D         4000      (6) 8/7/2016   Common Stock   4000     (4) 0   D    
Stock Option (Right to Buy)   $39.88   7/1/2014     D         4000      (7) 8/12/2017   Common Stock   4000     (4) 0   D    
Stock Option (Right to Buy)   $38.33   7/1/2014     D         4000      (8) 8/11/2018   Common Stock   4000     (4) 0   D    
Stock Option (Right to Buy)   $26.25   7/1/2014     D         4000      (9) 8/10/2019   Common Stock   4000     (4) 0   D    
Stock Option (Right to Buy)   $28.23   7/1/2014     D         5621      (10) 8/8/2020   Common Stock   5621     (4) 0   D    
Stock Option (Right to Buy)   $33.43   7/1/2014     D         5546      (11) 8/22/2021   Common Stock   5546     (4) 0   D    
Stock Option (Right to Buy)   $34.54   7/1/2014     D         7815      (12) 8/22/2022   Common Stock   7815     (4) 0   D    
Stock Option (Right to Buy)   $42.61   7/1/2014     D         5909      (13) 8/14/2023   Common Stock   5909     (4) 0   D    

Explanation of Responses:
( 1)  Each share of common stock was disposed of pursuant to the Merger Agreement, dated as of February 17, 2014 (the "Merger Agreement"), by and among the issuer and Actavis plc ("Actavis"), Tango US Holdings Inc., Tango Merger Sub 1 LLC, and Tango Merger Sub 2 LLC in exchange for either (A) $26.04 in cash plus 0.3306 Actavis ordinary shares having a market value of $224 per share on the effective date of the merger or (B) $25.67 in cash plus 0.332623 Actavis ordinary shares having a market value of $224 per share on the effective date of the merger, depending on the consideration election made by the reporting person and the consideration election proration procedures set forth in the Merger Agreement.
( 2)  Pursuant to the terms of the Merger Agreement, each restricted share of common stock converted as of the effective time of the transaction into the right to receive $103.43 in cash.
( 3)  The options are currently exercisable.
( 4)  Pursuant to the terms of the Merger Agreement, (a) each vested option to purchase issuer common stock was assumed by Actavis pursuant to the Merger Agreement and replaced with an option to purchase a number of whole Actavis ordinary shares equal to the product of (i) the number of shares of issuer common stock subject to such vested option multiplied by (ii) 0.4723, at an exercise price per share equal to the quotient obtained by dividing (x) the exercise price per share of such vested option by (y) 0.4723; and (b) each unvested option to purchase common stock converted as of the effective time of the transaction into the right to receive an amount in cash equal to the product of the excess, if any, of $103.43 over the exercise price per share of such unvested option multiplied by the number of shares of issuer common stock subject to such option.
( 5)  The options are currently exercisable.
( 6)  The options are currently exercisable.
( 7)  The options are currently exercisable.
( 8)  The options are currently exercisable.
( 9)  The options are currently exercisable.
( 10)  The options are currently exercisable.
( 11)  The options are currently exercisable.
( 12)  The options are currently exercisable.
( 13)  The options are currently exercisable.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
SALANS LESTER B
C/O FOREST LABORATORIES, INC.
909 THIRD AVENUE
NEW YORK, NY 10022 		X



Signatures
/s/ Rita Weinberger as attorney-in-fact for Lester B. Salans 7/2/2014
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Forest Road Acquisition Charts.
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Forest Road Acquisition Charts.